National Institute of Neurological Disorders and Stroke

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

Retrieved on: 
Tuesday, November 7, 2023
ACT, Bioenergetics, Microsoft Access, Science, EAP, Survival, FDA, Research, NINDS, Food, Mortality, CNM, Gold, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SALT, Engineering, ALS, Clinical trial, Medicine, Risk, Biology, Physics, MOA, Bangladesh Technical Education Board, Consultant, Columbia University, Small, Multiple sclerosis, NIH, DSM-IV codes, EAPS, Chemistry, Patient, Death, MS, National Institute of Neurological Disorders and Stroke, Cryptocurrency, Pharmaceutical industry, Stroke

In September, Clene announced long-term follow-up data for patients treated with CNM-Au8 for up to 133 weeks in the HEALEY ALS Platform Trial.

Key Points: 
  • In September, Clene announced long-term follow-up data for patients treated with CNM-Au8 for up to 133 weeks in the HEALEY ALS Platform Trial.
  • Clene expects that its resources as of September 30, 2023, will be sufficient to fund its operations into the third quarter of 2024.
  • Research and development expenses were $6.0 million for the quarter ended September 30, 2023, compared to $6.4 million for the same period in 2022.
  • General and administrative expenses were $3.7 million for the quarter ended September 30, 2023, compared to $3.6 million for the same period in 2022.

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Retrieved on: 
Thursday, October 5, 2023
ACT, Congress, ALS, Neuromuscular medicine, Columbia University Vagelos College of Physicians and Surgeons, MBA, Food, Doctor of Philosophy, Biomarker, Division, Research, Medicine, National Institute of Neurological Disorders and Stroke, FAAN, Master of Science, Neurology, NINDS, Safety, Columbia University, Survival, SALT, Disease, Surgeon, FDA, Collection, Clinical trial, DSM-IV codes, Microsoft Access, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Bangladesh Technical Education Board, MHS, CNM, Physician, 21st Century Cures Act, EAP, Patient, NIH, Pharmaceutical industry, MD, Stroke

In addition to this new EAP, Clene will continue to conduct its currently ongoing ALS EAP programs that have enrolled more than 200 participants since 2019.

Key Points: 
  • In addition to this new EAP, Clene will continue to conduct its currently ongoing ALS EAP programs that have enrolled more than 200 participants since 2019.
  • The EAP grant is part of the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS).
  • This EAP will provide eligible people living with ALS to work with their clinician to access CNM-Au8.
  • These data can help provide confirmatory support for the existing trial data Clene has gathered in its clinical trials.”
    This study is supported by NIH grant U01NS136023.

neuro42 Receives $5 Million NIH Grant for Research on Portable Intraoperative MRI for Neurosurgery

Retrieved on: 
Thursday, September 28, 2023
Epilepsy, Portable, Research, Bangladesh Technical Education Board, National Institute of Neurological Disorders and Stroke, DSM-IV codes, MRI, Neurosurgery, SAN, NINDS, Robotics, NIH, Medical imaging, Stroke

SAN FRANCISCO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- neuro42, Inc. (“neuro42” or the “Company”), a medical technology company leading the next evolution of MRI and robotics, today announced a $5 million grant from the National Institute of Health’s National Institute of Neurological Disorders and Stroke (NIH / NINDS) for research on Portable Intraoperative MRI for Neurosurgery.

Key Points: 
  • SAN FRANCISCO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- neuro42, Inc. (“neuro42” or the “Company”), a medical technology company leading the next evolution of MRI and robotics, today announced a $5 million grant from the National Institute of Health’s National Institute of Neurological Disorders and Stroke (NIH / NINDS) for research on Portable Intraoperative MRI for Neurosurgery.
  • With the award, neuro42 aims to advance MRI emerging modalities, such as MRI compatible robotic systems, for effectively guiding interventional procedures in neurosurgery.
  • “neuro42 is actively leading the industry in innovating MRI capabilities to optimize patient outcomes and enhance physician experience in an open, minimal footprint set up for interventional, robotic assisted neurosurgery,” said Abhita Batra, Founder and Chief Strategy Officer of neuro42.
  • The research indicated in this press release was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under Award Number U44NS136026.

College Athletes Experience Worse Post-Injury Outcomes for Concussions Suffered Outside of Sports

Retrieved on: 
Wednesday, September 20, 2023
Online, Concussion, NCAA, Male, Tactical Combat Casualty Care, DSM-IV codes, Consortium, CHOP, Traumatic brain injury, Stroke, Quality of life, Mind, National Collegiate Athletic Association, Falls, Doctor of Philosophy, Bangladesh Technical Education Board, Assistant, Non-sports trading card, Athlete, DOD, CARE, MD, Patient, Department of Defense Serum Repository, Sport, Knowledge, Hospital, Office of the Assistant Secretary for Health, Assistant Secretary of Defense for Health Affairs, Joint Program in Survey Methodology, National Institute of Neurological Disorders and Stroke, Female, Injury, Children's Hospital of Philadelphia, Nursing, Defense, Research, Education

PHILADELPHIA, Sept. 20, 2023 /PRNewswire/ -- Researchers from Children's Hospital of Philadelphia (CHOP) found that college athletes had worse post-injury outcomes related to concussions they experienced outside of sports than those they experienced while playing sports. Additionally, female athletes who sustained their injury outside of sports had more severe symptoms and more days in sports lost to injury relative to male athletes. These findings suggest the need for improved concussion recognition, reporting, and monitoring outside of sports.

Key Points: 
  • PHILADELPHIA, Sept. 20, 2023 /PRNewswire/ -- Researchers from Children's Hospital of Philadelphia (CHOP) found that college athletes had worse post-injury outcomes related to concussions they experienced outside of sports than those they experienced while playing sports.
  • Additionally, female athletes who sustained their injury outside of sports had more severe symptoms and more days in sports lost to injury relative to male athletes.
  • Concussions have the potential to impact the daily function and quality of life of those who sustain them.
  • Some research has indicated that patients with non-sports-related concussions have worse outcomes, but research into those effects in college-age patients is very limited.

New Community Partnership Model Boosts Participant Inclusion into HIV Cure-Directed Research

Retrieved on: 
Tuesday, August 8, 2023
Partnership, Cell biology, University, CAB, DATE, HIV, National Institute of Mental Health, Culture, HIV-1, Policy, Infection, Cancer, Stroke, Mental health, Biomedical Research, Community advisory board, University of California, San Diego, Research, History, CEG, Person, The Philadelphia Foundation, Organization, National Institute of Neurological Disorders and Stroke, DSM-IV codes, Community, Trust, AIDS, Patient, Wistar Institute, National Institute on Drug Abuse, United States Military HIV Research Program, Montaner, Team, National Institute of Allergy and Infectious Diseases, Pharmaceutical industry, Medical device, Engagement, Wistar

Now, researchers from The Wistar Institute are sharing how a more inclusive model for community engagement can lead to deeper insights and greater community participation in HIV research.

Key Points: 
  • Now, researchers from The Wistar Institute are sharing how a more inclusive model for community engagement can lead to deeper insights and greater community participation in HIV research.
  • The community engagement group, or CEG model, is composed of a three-part structure with a Community Advisory Board (CAB), Community nonprofit organization, and researchers.
  • , vice president for scientific operations, Herbert Kean, M.D., Family Professor , director, HIV-1 Immunopathogenesis Laboratory, and leader, HIV Research Program , Vaccine & Immunotherapy Center at The Wistar Institute.
  • Publication information: “Community engagement group model in basic and biomedical research: lessons learned from the BEAT-HIV Delaney Collaboratory towards an HIV-1 cure,” Research Involvement and Engagement (DATE).

Coya Therapeutics (“Coya”) Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor to Support the Development of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Retrieved on: 
Wednesday, July 19, 2023
Biotechnology, Pharmaceutical, Health, Neurology, Merit Cudkowicz, International, Harvard–MIT Program in Health Sciences and Technology, Life, Outline of health sciences, Clinical trial, American Academy, Boston, COYA, Forbes Norris, Harvard Medical School, National Institute of Neurological Disorders and Stroke, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, DSM-IV codes, Massachusetts Institute of Technology, Public health, Beth Israel Hospital, Patient, Coya, Chemical engineering, Master of Science, Hospital, American Academy of Neurology, Massachusetts General Hospital, Therapy, ALS, Harvard School of Dental Medicine, Commerce, Pharmaceutical industry, MD

Dr. Cudkowicz is a world-renowned neurologist who has dedicated her career to improving the life of patients with ALS and other serious neurological conditions.

Key Points: 
  • Dr. Cudkowicz is a world-renowned neurologist who has dedicated her career to improving the life of patients with ALS and other serious neurological conditions.
  • Dr. Cudkowicz brings decades of experience supporting the development of new therapies for ALS.
  • Dr. Cudkowicz has launched the first platform trial initiative in ALS, the HEALEY ALS Platform Trial, a program that helps accelerate therapy development in ALS.
  • Merit Cudkowicz commented: "I am happy to join Coya as a clinical advisor as they move COYA 302 into a well powered and designed clinical trial.

Cartesian Therapeutics Announces Landmark Study in The Lancet Neurology of First Successful Clinical Trial of RNA Cell Therapy in Autoimmunity

Retrieved on: 
Thursday, June 22, 2023
Research, Neurology, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, University, Therapy, Lancet Neurology, Phase II, Neurotoxicity, Efficacy, Immunoglobulin therapy, Clinical trial, Bone marrow, Oregon Health & Science University, NIH, Chapel Hill, DRS, University of South Florida, Myasthenia gravis, RNA, Autoimmunity, University of Miami, Bangladesh Technical Education Board, CAR, DSM-IV codes, National Institute of Neurological Disorders and Stroke, Cytokine release syndrome, MG, Patient, Physician, Northwestern Health Sciences University, Autotransplantation, NINDS, Paper, Toxic encephalopathy, American Neurological Association, Immunosuppression, Myasthenia, The Lancet, Lancet, Safety, Pharmaceutical industry, Vaccine, Stroke, Cartesian

Cartesian Therapeutics , a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology.

Key Points: 
  • Cartesian Therapeutics , a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology.
  • The study describes Descartes-08, a cutting-edge RNA CAR-T (rCAR-T) therapy administered to patients with generalized myasthenia gravis (MG), a debilitating autoimmune neurological disease.
  • This is the first clinical trial using rCAR-T to treat autoimmunity, and the first successful Phase 2 trial using an engineered cell therapy to treat autoimmunity.
  • Clinical benefit was sustained long-term for most patients, even months after completing the course of therapy.

Virpax Pharmaceuticals Enters into CRADA with the National Advisory Neurological Disorders and Stroke Council

Retrieved on: 
Wednesday, June 21, 2023
Research, Other Health, Pharmaceutical, Medical Devices, Infectious Diseases, Hospitals, Surgery, Science, Veterinary, Neurology, Biotechnology, Practice Management, Health, Epilepsy, Translation, Central nervous system, Systemic disease, CRADA, Brain, CNS, National Institute of Neurological Disorders and Stroke, DSM-IV codes, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Post-traumatic stress disorder, Pain management, NINDS, MET, FDA, NIH, Pharmaceutical industry, Stroke, CBD

Under the CRADA, NINDS ETSP will evaluate Virpax’s NobrXiol™ product candidate that is being developed for the management of rare pediatric epilepsy.

Key Points: 
  • Under the CRADA, NINDS ETSP will evaluate Virpax’s NobrXiol™ product candidate that is being developed for the management of rare pediatric epilepsy.
  • NobrXiol utilizes a unique intranasal Molecular Envelope Technology (MET) delivery platform for pharmaceutical-grade cannabidiol (CBD).
  • ETSP provides opportunities for researchers in the US and abroad to submit compounds for screening in a battery of rodent epilepsy and seizure models.
  • There is no cost to participants for these tests and the ETSP staff provides advice on next steps for promising compounds.

Independent clinical study shows Curonix’s Freedom® PNS System significantly reduces pain scores and medication usage

Retrieved on: 
Wednesday, June 7, 2023
Freedom, PMID, Peripheral nerve stimulation, Stroke, Quality of life, Interventionism, DSM-IV codes, PNS, Journal, Patient, Risk, NINDS, Peripheral neuropathy, Chronic pain, Journal of Pain Research, SPSS, National Institute of Neurological Disorders and Stroke, Dentistry, Birth control, Pain

The results showed that patients significantly reduced both pain scores and medication usage, highlighting the Freedom PNS System as a successful, long-term, and less invasive treatment option for patients suffering from chronic pain.

Key Points: 
  • The results showed that patients significantly reduced both pain scores and medication usage, highlighting the Freedom PNS System as a successful, long-term, and less invasive treatment option for patients suffering from chronic pain.
  • This independent retrospective study reviewed the electronic medical records of 57 patients over 24 months who were treated for different pain neuralgias with the Freedom PNS technology.
  • This further supports that the Freedom PNS System is an efficient and powerful treatment option for patients seeking long-term relief from their chronic pain.
  • Long-term consequences of chronic pain: mounting evidence for pain as a neurological disease and parallels with other chronic disease states.

Research to develop new rare disease therapies underway at The Jackson Laboratory

Retrieved on: 
Tuesday, June 6, 2023
Tissue, Huntington's disease, DNA, CRISPR, Broad Institute, Therapy, Spinal muscular atrophy, DSM-IV codes, Boston Children's Hospital, Rett syndrome, Hope, Research, Jackson Laboratory, Associate, Friedreich's ataxia, National Institute of Neurological Disorders and Stroke, SCGE, University of Texas Southwestern Medical Center, Patient, Risk, Nervous system, JAX, NINDS, Hospital, Rare, FDA, Massachusetts General Hospital, BAR, Lutz, IND, Disease, Vaccine, Pharmaceutical industry, Stroke

 BAR HARBOR, Maine, June 6, 2023 /PRNewswire/ -- Researchers led by Cathleen Lutz, Ph.D., are using an exciting new method, preclinical genomic editing, to develop safe, effective therapies for rare diseases and bring them to the clinic.

Key Points: 
  • Unfortunately, the translation of the accumulated knowledge to safe and effective therapies has lagged.
  • Researchers are therefore still hard at work to develop safer therapies for rare genetic diseases that provide lasting benefit.
  • Now Cathleen Lutz , Ph.D., of The Jackson Laboratory (JAX) is spearheading a major effort to implement a new genomic research tool—preclinical genomic editing—to cure rare neurological genetic diseases.
  • Collectively they seek to close the gap between preclinical research that has produced promising rare disease therapy strategies and the actual clinical delivery of safe and effective treatments to patients.